{"_links":{"self":[{"href":"/project/GID-HST10037"}]},"_embedded":{"nice.indev:timeline-list":{"_links":{"self":[{}]},"_embedded":{"nice.indev:timeline":[{"_links":{"self":[{}]},"ETag":null,"Column1":"01 March 2022","Column2":"Suspended. On 23 February 2022, the company (Orphazyme) issued a statement that it is currently assessing its strategic options following feedback on arimoclomol from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP). Therefore, this evaluation will be suspended. NICE will continue to monitor any developments and will update stakeholders if the situation changes.","AdditionalInfoLabel":"Link text","AdditionalInfo":null,"Hidden":false},{"_links":{"self":[{}]},"ETag":null,"Column1":"17 December 2021","Column2":"Invitation to participate","AdditionalInfoLabel":null,"AdditionalInfo":null,"Hidden":false},{"_links":{"self":[{}]},"ETag":null,"Column1":"17 May 2021","Column2":"Please note that following on from advice received from the company this evaluation has been rescheduled. Therefore, we now anticipate that the evaluation will begin during early November 2021 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately mid-Jan 2022.","AdditionalInfoLabel":null,"AdditionalInfo":null,"Hidden":false},{"_links":{"self":[{}]},"ETag":null,"Column1":"09 October 2020 (14:00)","Column2":"Scoping workshop","AdditionalInfoLabel":"Location of meeting","AdditionalInfo":null,"Hidden":false},{"_links":{"self":[{}]},"ETag":null,"Column1":"19 August 2020 - 17 September 2020","Column2":"Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators","AdditionalInfoLabel":null,"AdditionalInfo":null,"Hidden":false}]},"ETag":null},"nice.indev:process-homepage":{"_links":{"self":[{"href":"https://www.nice.org.uk/process/pmg20/chapter/introduction"},{}]},"ETag":null,"Description":"For further information on our processes and methods, please see our","LinkText":"CHTE processes and methods manual default"},"nice.indev:project-team-list":{"_links":{"self":[{}]},"_embedded":{"nice.indev:project-team":{"_links":{"self":[{}]},"ETag":null,"Column1":"Project lead","Column2":"Gavin Kenny"}},"ETag":null},"nice.indev:email-enquiry-list":{"_links":{"self":[{}]},"_embedded":{"nice.indev:email-enquiry":{"_links":{"self":[{}]},"ETag":null,"Item":"hst6@nice.org.uk"}},"ETag":null},"nice.indev:consultee-list":{"_links":{"self":[{}]},"_embedded":{"nice.indev:consultee":[{"_links":{"self":[{}]},"ETag":null,"Column1":"Companies sponsors","Column2":"•\tOrphazyme (arimoclomol)"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Others","Column2":"•\tAddenbrooke's Lysosomal Disorders Unit"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Others","Column2":"•\tBirmingham Children’s Hospital NHS Foundation Trust Lysosomal Storage Disorders Unit"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Others","Column2":"•\tDepartment of Health and Social Care"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Others","Column2":"•\tGreat Ormond Street Hospital Metabolic Unit"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Others","Column2":"•\tNHS England"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Others","Column2":"•\tRoyal Free Lysosomal Storage Disorders Unit"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Others","Column2":"•\tRoyal Manchester Children’s Hospital"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Others","Column2":"•\tSalford Royal NHS Foundation Trust Mark Holland Metabolic Unit"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Others","Column2":"•\tUniversity College London Hospitals NHS Foundation Trust Lysosomal Disorders Unit"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Others","Column2":"•\tWillink Unit, Genetic Medicine, Central Manchester Foundation Trust"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Patient carer groups","Column2":"•\tBrain Charity"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Patient carer groups","Column2":"•\tContact"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Patient carer groups","Column2":"•\tFindacure"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Patient carer groups","Column2":"•\tGenetic Alliance UK"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Patient carer groups","Column2":"•\tGene People"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Patient carer groups","Column2":"•\tMetabolic Support UK"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Patient carer groups","Column2":"•\tNeurological Alliance"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Patient carer groups","Column2":"•\tNiemann-Pick UK"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Patient carer groups","Column2":"•\tSouth Asian Health Foundation"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Patient carer groups","Column2":"•\tSpecialised Healthcare Alliance"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Patient carer groups","Column2":"•\tUK LSD Patient Collaborative Group"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Professional groups","Column2":"•\tAssociation of British Neurologists"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Professional groups","Column2":"•\tAssociation of Genetic Nurses and Counsellors"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Professional groups","Column2":"•\tBritish Association for the Study of the Liver"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Professional groups","Column2":"•\tBritish Association of Occupational Therapists and College of Occupational Therapists"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Professional groups","Column2":"•\tBritish Inherited Metabolic Disease Group"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Professional groups","Column2":"•\tBritish Neuropathological Society"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Professional groups","Column2":"•\tBritish Paediatric Neurology Association"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Professional groups","Column2":"•\tBritish Society for Gene and Cell Therapy  "},{"_links":{"self":[{}]},"ETag":null,"Column1":"Professional groups","Column2":"•\tBritish Society for Genetic Medicine"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Professional groups","Column2":"•\tInstitute of Neurology"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Professional groups","Column2":"•\tNational Metabolic Biochemistry Network"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Professional groups","Column2":"•\tNeonatal and Paediatric Pharmacists Group"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Professional groups","Column2":"•\tRoyal College of General Practitioners"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Professional groups","Column2":"•\tRoyal College of Nursing"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Professional groups","Column2":"•\tRoyal College of Paediatrics & Child Health"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Professional groups","Column2":"•\tRoyal College of Pathologists "},{"_links":{"self":[{}]},"ETag":null,"Column1":"Professional groups","Column2":"•\tRoyal College of Physicians"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Professional groups","Column2":"•\tRoyal Pharmaceutical Society"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Professional groups","Column2":"•\tRoyal Society of Medicine "},{"_links":{"self":[{}]},"ETag":null,"Column1":"Professional groups","Column2":"•\tUK Clinical Pharmacy Association"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Professional groups","Column2":"•\tUK Genetic Testing Network"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Professional groups","Column2":"•\tUK Health Forum"}]},"ETag":null},"nice.indev:commentator-list":{"_links":{"self":[{}]},"_embedded":{"nice.indev:commentator":[{"_links":{"self":[{}]},"ETag":null,"Column1":"Associated public health groups","Column2":"•\tPublic Health Wales "},{"_links":{"self":[{}]},"ETag":null,"Column1":"Associated public health groups","Column2":"•\tUK Health Security Agency"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Comparator companies","Column2":"•\tAccord Healthcare (miglustat)"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Comparator companies","Column2":"•\tJanssen (miglustat)"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Comparator companies","Column2":"•\tPiramal Critical Care (miglustat"},{"_links":{"self":[{}]},"ETag":null,"Column1":"General commentators","Column2":"•\tAll Wales Therapeutics and Toxicology Centre"},{"_links":{"self":[{}]},"ETag":null,"Column1":"General commentators","Column2":"•\tAllied Health Professionals Federation"},{"_links":{"self":[{}]},"ETag":null,"Column1":"General commentators","Column2":"•\tBoard of Community Health Councils in Wales"},{"_links":{"self":[{}]},"ETag":null,"Column1":"General commentators","Column2":"•\tBritish National Formulary"},{"_links":{"self":[{}]},"ETag":null,"Column1":"General commentators","Column2":"•\tCare Quality Commission"},{"_links":{"self":[{}]},"ETag":null,"Column1":"General commentators","Column2":"•\tCell and Gene Therapy Catapult"},{"_links":{"self":[{}]},"ETag":null,"Column1":"General commentators","Column2":"•\tDepartment of Health, Social Services and Public Safety for Northern Ireland"},{"_links":{"self":[{}]},"ETag":null,"Column1":"General commentators","Column2":"•\tHealthcare Improvement Scotland"},{"_links":{"self":[{}]},"ETag":null,"Column1":"General commentators","Column2":"•\tInherited Metabolic and Lysosomal Disease Service, Cardiff and Vale UHB"},{"_links":{"self":[{}]},"ETag":null,"Column1":"General commentators","Column2":"•\tMedicines and Healthcare products Regulatory Agency "},{"_links":{"self":[{}]},"ETag":null,"Column1":"General commentators","Column2":"•\tNational Association of Primary Care"},{"_links":{"self":[{}]},"ETag":null,"Column1":"General commentators","Column2":"•\tNational Pharmacy Association"},{"_links":{"self":[{}]},"ETag":null,"Column1":"General commentators","Column2":"•\tNational Services Division"},{"_links":{"self":[{}]},"ETag":null,"Column1":"General commentators","Column2":"•\tNHS Alliance"},{"_links":{"self":[{}]},"ETag":null,"Column1":"General commentators","Column2":"•\tNHS Confederation"},{"_links":{"self":[{}]},"ETag":null,"Column1":"General commentators","Column2":"•\tScottish Medicines Consortium"},{"_links":{"self":[{}]},"ETag":null,"Column1":"General commentators","Column2":"•\tWelsh Government"},{"_links":{"self":[{}]},"ETag":null,"Column1":"General commentators","Column2":"•\tWelsh Health Specialised Services Committee"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Relevant research groups","Column2":"•\tBrain Research UK"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Relevant research groups","Column2":"•\tCochrane Hepato-Biliary Group"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Relevant research groups","Column2":"•\tCochrane Metabolic & Endocrine Disorders Group"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Relevant research groups","Column2":"•\tCochrane UK"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Relevant research groups","Column2":"•\tGenomics England"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Relevant research groups","Column2":"•\tMRC Clinical Trials Unit"},{"_links":{"self":[{}]},"ETag":null,"Column1":"Relevant research groups","Column2":"•\tNational Institute for Health Research"}]},"ETag":null},"nice.indev:panel-list":{"_links":{"self":[{}]},"_embedded":{"nice.indev:panel":[{"_links":{"self":[{}]},"_embedded":{"nice.indev:resource-list":{"_links":{"self":[{}]},"_embedded":{"nice.indev:resource":[{"_links":{"self":[{}]},"_embedded":{"nice.indev:file":{"_links":{"self":[{"href":"/guidance/GID-HST10037/documents/final-scope"}]},"ETag":null,"Id":"95e094f8-cf5a-41d8-9531-0e9764960180","MimeType":"application/pdf","FileName":"ID1312 arimoclomol NPC scope to PM for ITP [noACIC].pdf","Length":198188,"Hash":"123C96DF90255A31E54846DD308B53C69E7DFAED","Name":"default","Reference":"GID-HST10037","ResourceTitleId":"final-scope","ConsultationDocumentId":0}},"ETag":null,"Title":"Final scope","Level":1,"PublishedDate":"2021-12-17T00:00:00","ExternalUrl":null,"ShowInDocList":true,"TextOnly":false,"ConsultationId":0,"ConsultationDocumentId":0,"IsCurrentViewableConsultationMarkup":false,"ConvertedDocument":false,"SupportsComments":false},{"_links":{"self":[{}]},"_embedded":{"nice.indev:file":{"_links":{"self":[{"href":"/guidance/GID-HST10037/documents/equality-impact-assessment-scoping"}]},"ETag":null,"Id":"d4daec42-97bc-4b2c-a379-588dd77850f3","MimeType":"application/pdf","FileName":"ID1312 Niemann-Pick disease EIA scoping to PM for ITP [noACIC].pdf","Length":124193,"Hash":"BB93CCCAFD15A2D614A11D85716883AF2C0DB82C","Name":"default","Reference":"GID-HST10037","ResourceTitleId":"equality-impact-assessment-scoping","ConsultationDocumentId":0}},"ETag":null,"Title":"Equality impact assessment (Scoping)","Level":1,"PublishedDate":"2021-12-17T00:00:00","ExternalUrl":null,"ShowInDocList":true,"TextOnly":false,"ConsultationId":0,"ConsultationDocumentId":0,"IsCurrentViewableConsultationMarkup":false,"ConvertedDocument":false,"SupportsComments":false},{"_links":{"self":[{}]},"_embedded":{"nice.indev:file":{"_links":{"self":[{"href":"/guidance/GID-HST10037/documents/final-matrix"}]},"ETag":null,"Id":"62f3fae5-d8c0-4548-a36e-a9933cef9d9b","MimeType":"application/pdf","FileName":"ID1312 Niemann-Pick type C - arimoclomol final matrix to PM for ITP [noACIC].pdf","Length":195697,"Hash":"90C85C0DD8B29260ED68F55C4481FB1A1F82A29A","Name":"default","Reference":"GID-HST10037","ResourceTitleId":"final-matrix","ConsultationDocumentId":0}},"ETag":null,"Title":"Final stakeholder list","Level":1,"PublishedDate":"2021-12-17T00:00:00","ExternalUrl":null,"ShowInDocList":true,"TextOnly":false,"ConsultationId":0,"ConsultationDocumentId":0,"IsCurrentViewableConsultationMarkup":false,"ConvertedDocument":false,"SupportsComments":false},{"_links":{"self":[{}]},"_embedded":{"nice.indev:file":{"_links":{"self":[{"href":"/guidance/GID-HST10037/documents/scope-consultation-comments-and-responses"}]},"ETag":null,"Id":"8ea574fe-65ce-4822-bfd9-a6648eadaa49","MimeType":"application/pdf","FileName":"ID1312 NPC arimoclomol scoping cons comments table to PM for ITP [noACIC].pdf","Length":292446,"Hash":"7DE338F2B57FBD4D50321388AC711B5C9D396C91","Name":"default","Reference":"GID-HST10037","ResourceTitleId":"scope-consultation-comments-and-responses","ConsultationDocumentId":0}},"ETag":null,"Title":"NICE's response to comments on the draft scope and provisional stakeholder list","Level":1,"PublishedDate":"2021-12-17T00:00:00","ExternalUrl":null,"ShowInDocList":true,"TextOnly":false,"ConsultationId":0,"ConsultationDocumentId":0,"IsCurrentViewableConsultationMarkup":false,"ConvertedDocument":false,"SupportsComments":false}]},"ETag":null,"HasResources":true}},"ETag":null,"Title":"Invitation to participate","PanelType":"History","LegacyPanel":false,"OriginalReference":null,"UpdateReference":null,"ShowPanel":true},{"_links":{"self":[{}]},"_embedded":{"nice.indev:resource-list":{"_links":{"self":[{}]},"_embedded":{"nice.indev:resource":[{"_links":{"self":[{}]},"_embedded":{"nice.indev:file":{"_links":{"self":[{"href":"/guidance/GID-HST10037/documents/html-content"}]},"ETag":null,"Id":"c8ff0b31-4935-4790-aeb0-7a0dda7d100e","MimeType":"text/html","FileName":"HtmlContent","Length":0,"Hash":"0631457264FF7F8D5FB1EDC2C0211992A67C73E6","Name":"default","Reference":"GID-HST10037","ResourceTitleId":"html-content","ConsultationDocumentId":0}},"ETag":null,"Title":"Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators","Level":1,"PublishedDate":"2020-08-19T16:12:00","ExternalUrl":null,"ShowInDocList":true,"TextOnly":false,"ConsultationId":1038,"ConsultationDocumentId":0,"IsCurrentViewableConsultationMarkup":false,"ConvertedDocument":false,"SupportsComments":false},{"_links":{"self":[{}]},"_embedded":{"nice.indev:file":{"_links":{"self":[{"href":"/guidance/GID-HST10037/documents/draft-scope-post-referral"}]},"ETag":null,"Id":"170b7050-cd3b-430a-8f2b-12ab265415f7","MimeType":"application/pdf","FileName":"Appendix B - draft scope.pdf","Length":213861,"Hash":"16C358DD17FFC6B0CE6B976E7FB57974AF72148E","Name":"default","Reference":"GID-HST10037","ResourceTitleId":"draft-scope-post-referral","ConsultationDocumentId":0}},"ETag":null,"Title":"Draft scope post referral","Level":1,"PublishedDate":"2020-08-19T16:12:00","ExternalUrl":null,"ShowInDocList":true,"TextOnly":false,"ConsultationId":1038,"ConsultationDocumentId":0,"IsCurrentViewableConsultationMarkup":false,"ConvertedDocument":false,"SupportsComments":false},{"_links":{"self":[{}]},"_embedded":{"nice.indev:file":{"_links":{"self":[{"href":"/guidance/GID-HST10037/documents/draft-matrix-post-referral"}]},"ETag":null,"Id":"057527b8-5405-4d5f-b504-e2060e75b78e","MimeType":"application/pdf","FileName":"Appendix C - stakeholder list.pdf","Length":194754,"Hash":"AC5D0934F036F07CA0BB58F18AA69141ADD5B639","Name":"default","Reference":"GID-HST10037","ResourceTitleId":"draft-matrix-post-referral","ConsultationDocumentId":0}},"ETag":null,"Title":"Draft matrix post referral","Level":1,"PublishedDate":"2020-08-19T16:12:00","ExternalUrl":null,"ShowInDocList":true,"TextOnly":false,"ConsultationId":1038,"ConsultationDocumentId":0,"IsCurrentViewableConsultationMarkup":false,"ConvertedDocument":false,"SupportsComments":false}]},"ETag":null,"HasResources":true}},"ETag":null,"Title":"Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators","PanelType":"History","LegacyPanel":false,"OriginalReference":null,"UpdateReference":null,"ShowPanel":true}]},"ETag":null}},"ETag":"01000000-0000-0001-0000-000000000608","Summary":"Suggested remit: To evaluate the benefits and costs of arimoclomol within its marketing authorisation for treating Niemann-Pick disease type C for national commissioning by NHS England.","Description":null,"ReferralDate":null,"SuspendDiscontinuedReason":"On 23 February 2022, the company (Orphazyme) issued a statement that it is currently assessing its strategic options following feedback on arimoclomol from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP). Therefore, this evaluation will be suspended. NICE will continue to monitor any developments and will update stakeholders if the situation changes.","SuspendDiscontinuedUrl":null,"SuspendDiscontinuedUrlText":null,"LegacyModel":false,"ProductReference":null,"EvidenceAssessmentGroup":null,"Reference":"GID-HST10037","ProjectType":"HST","TechnologyType":null,"ProductTypeName":"Highly specialised technology","Process":"HST","Title":"Arimoclomol for treating Niemann-Pick disease Type C [ID1312]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2022-03-01T17:35:34.2085386","FirstGoLiveDate":"2020-08-19T16:13:34.654045","CreatedDate":"2020-08-19T16:09:10.1269434","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1312","AreasOfInterestList":[],"TopicSelectionDecision":"Selected","TopicSelectionReason":null,"TopicSelectionDecisionDate":null,"TopicSelectionFurtherInfo":null,"IndicatorSubTypes":[]}